CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $115.00 by Analysts at Piper Sandler

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) had its price objective decreased by investment analysts at Piper Sandler from $180.00 to $115.00 in a research report issued on Monday, The Fly reports. Piper Sandler’s target price would indicate a potential upside of 104.12% from the stock’s previous close.

CRSP has been the topic of several other research reports. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $95.00 to $85.00 in a report on Tuesday, May 10th. Brookline Capital Management reaffirmed a “buy” rating and issued a $143.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, February 14th. Oppenheimer reduced their price objective on shares of CRISPR Therapeutics from $172.00 to $150.00 in a research report on Wednesday, May 11th. Truist Financial reaffirmed a “buy” rating and issued a $220.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, February 16th. Finally, Brookline Capital Acquisition started coverage on shares of CRISPR Therapeutics in a research report on Monday, February 14th. They issued a “buy” rating and a $143.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $121.19.

Shares of NASDAQ CRSP opened at $56.34 on Monday. The firm’s 50-day moving average price is $58.69 and its 200-day moving average price is $66.30. CRISPR Therapeutics has a 1-year low of $42.51 and a 1-year high of $169.76. The firm has a market capitalization of $4.36 billion, a P/E ratio of 15.61 and a beta of 2.05.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.38). CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. The company had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. During the same quarter in the prior year, the company posted ($1.51) EPS. CRISPR Therapeutics’s revenue for the quarter was up 74.4% on a year-over-year basis. Sell-side analysts forecast that CRISPR Therapeutics will post -8.97 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of CRSP. Capital Impact Advisors LLC purchased a new position in CRISPR Therapeutics in the 4th quarter worth $26,000. Elkhorn Partners Limited Partnership raised its position in CRISPR Therapeutics by 180.0% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after purchasing an additional 225 shares during the period. Kistler Tiffany Companies LLC raised its position in CRISPR Therapeutics by 6,250.0% in the 4th quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after purchasing an additional 375 shares during the period. CI Investments Inc. purchased a new position in CRISPR Therapeutics in the 3rd quarter worth $30,000. Finally, IronBridge Private Wealth LLC purchased a new position in CRISPR Therapeutics in the 4th quarter worth $30,000. Institutional investors own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles